Obesity is increasingly recognized as a common comorbidity in patients with inflammatory bowel disease (IBD). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for weight reduction and cardiometabolic risk management. However, their safety and effectiveness in individuals with inflammatory bowel disease remain uncertain. They conducted a systematic review through June 2025 to identify studies involving adult patients with inflammatory bowel disease treated with GLP-1RAs. Primary outcomes included hospitalization, corticosteroid use, treatment escalation, risk of flare, and inflammatory bowel disease-related surgery. Secondary outcomes were changes in weight and body mass index (BMI).
Results: A total of 10 observational studies, comprising 10,362 patients with inflammatory bowel disease (3,479 receiving GLP-1 RAs and 6,883 receiving placebo or other anti-obesity medications), were included. The pooled incidences of hospitalization, corticosteroid use, treatment escalation, flare, and surgery among patients receiving GLP-1RAs were 11%, 11%, 8%, 14%, and 3%, respectively. Use of GLP-1RAs in inflammatory bowel disease patients was not associated with an increased risk of corticosteroid use (OR: 0.93; 95% CI: 0.17–5.16; I2 = 11.4%), treatment escalation (OR: 0.70; 95% CI: 0.06–7.62; I2 = 0%), or inflammatory bowel disease-related surgery (OR: 0.32; 95% CI: 0.00–313.88; I2 = 92.5%) compared to non–GLP-1 users. Patients treated with GLP-1RAs achieved a percentage total body weight loss of 6.67% (95% CI: 2.93%–10.40%; I2 = 0%), a mean absolute weight loss of 7.33 kg (95% CI: 6.03–8.63; I2 = 0%) and a BMI reduction of 2.48 kg/m2 (95% CI: 0.79–4.17; I2 = 0%) compared to baseline. GLP-1 receptor agonists appear to be safe and effective in patients with inflammatory bowel disease.
Reference:
Noppachai Siranart, Pannathorn Nakaphan, Patavee Pajareya, Khamik Laohasurayotin, Can GLP-1 Agonists Be Used Safely in IBD? A Meta-Analysis, Journal of Crohn's and Colitis, 2025;, jjaf193, https://doi.org/10.1093/ecco-jcc/jjaf193
Keywords:
GLP-1 receptor, agonists, appear safe, effective, patients, IBD, Inflammatory Bowel Disease, GLP-1 Receptor Agonists, Obesity, Corticosteroids, Hospitalization, obesity, adrenal corticosteroids, inflammatory, bowel, disease, glucocorticoids, mineral, cocorticoids, glucagon-like peptide-1 agonists
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.